Document is current
Any future updates will be listed below
-
Authors
Buemi, Valentina
Schillaci, Odessa
Santorsola, Mariangela https://orcid.org/0000-0001-8514-932X
Bonazza, Deborah
Broccia, Pamela Veneziano
Zappone, Annie
Bottin, Cristina
Dell’Omo, Giulia
Kengne, Sylvie
Cacchione, Stefano https://orcid.org/0000-0002-7278-3695
Raffa, Grazia Daniela https://orcid.org/0000-0002-5072-5240
Piazza, Silvano
di Fagagna, Fabrizio d’Adda https://orcid.org/0000-0002-9603-5966
Benetti, Roberta https://orcid.org/0000-0001-8863-0821
Cortale, Maurizio
Zanconati, Fabrizio
Del Sal, Giannino https://orcid.org/0000-0003-2185-6003
Schoeftner, Stefan https://orcid.org/0000-0002-8918-6627
-
Funding
Funding for this research was provided by:
Agenzia Spaziale Italiana (2016-6-U0)
Fondazione Telethon (GPP13147, GGP17111)
Associazione Italiana per la Ricerca sul Cancro (21091, 17756, 22759, 22174, 23074)
EC | European Regional Development Fund (ITAT1096-P, ITAT1050, ITAT1096-P, ITAT1050)
- License Information
-
More Information
Article History
Received: 9 November 2020
Accepted: 25 March 2022
First Online: 28 April 2022
Competing interests
: G:D.R, S.C, and S.S. are inventors on patent applications related to chemical inhibition of TGS1 in telomere diseases (“Pharmaceutical composition for the chemical inhibition of TGS1 as therapeutic treatment for telomeropathies”; PCT/IB2021/054484). Other authors declare no competing interest.
